v3.24.1
Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity/(Deficit) - USD ($)
$ in Thousands
Total
Common Stock [Member]
Preferred Stock [Member]
Convertible Preferred Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Accumulated Other Comprehensive Income/(Loss) [Member]
Beginning balance at Dec. 31, 2021 $ (17,249) $ 0 $ 21,348 $ 143 $ (17,392) $ 0
Beginning balance, shares at Dec. 31, 2021   875,279 10,329,265      
Issuance of convertible preferred stock, net of issuance costs     $ 96,676      
Issuance of convertible preferred stock, net of issuance costs, shares     23,007,017      
Stock-based compensation expense 1,518     1,518    
Net loss (28,476)       (28,476)  
Other comprehensive income (loss) (161)         (161)
Ending balance at Dec. 31, 2022 (44,368) $ 0 $ 118,024 1,661 (45,868) (161)
Ending balance, shares at Dec. 31, 2022   875,279 33,336,282      
Exercise of common stock options 5 $ 1   4    
Exercise of common stock options, shares   2,798        
Conversion of convertible preferred stock to common stock in connection with the Reverse Merger 118,024 $ 1 $ (118,024) 118,023    
Conversion of convertible preferred stock to common stock in connection with the Reverse Merger, shares   7,269,183 (33,336,282)      
Issuance of common stock and pre-funded warrants in the pre-closing financing, net of issuance costs 67,750     67,750    
Issuance of common stock and pre-funded warrants in the pre-closing financing, net of issuance costs, shares   2,873,988        
Issuance of common stock to former stockholders of Magenta Therapeutics, Inc. in connection with the Reverse Merger 71,825     71,825    
Issuance of common stock to former stockholders of MagentaTherapeutics, Inc. in connection with the Reverse Merger, shares   3,796,448        
Adjustment for change in common stock par value in connection with the Reverse Merger   $ 13   (13)    
Reverse recapitalization transaction costs (3,919)     (3,919)    
Stock-based compensation expense 2,900     2,900    
Net loss (43,555)       (43,555)  
Other comprehensive income (loss) 208         208
Ending balance at Dec. 31, 2023 $ 168,870 $ 15 $ 0 $ 258,231 $ (89,423) $ 47
Ending balance, shares at Dec. 31, 2023   14,817,696 0